Lymphogranuloma venereum (LGV) is an infectious disease caused by the bacteria Chlamydia trachomatis, which is transmitted mainly through sexual contact. This disease is characterized by the formation of lymphadenopathy, suppuration and nodules in the lymph nodes, and can also lead to the formation of ulcers on the genitals. It is important to note that LGV is often associated with other sexually transmitted diseases, which complicates diagnosis and requires a careful approach to treatment. Modern society is faced with problems of increasing morbidity, which makes it necessary to understand this pathology and optimize methods of its treatment and prevention.
History of the disease and interesting historical facts
Lymphogranuloma venereum was first described in the late 19th century and has undergone a number of changes in attitudes towards diagnosis and treatment since then. In 1905, it was established that the causative agent of LGV is chlamydia, but clinical studies of the manifestations and consequences of the disease began much later. Interestingly, LGV became widely known during the Florentine quarantine in the mid-20th century, when the incidence of the disease increased sharply among prostitutes and their clients. At this time, active study of the prevalence of the disease and its mechanism of transmission began, which contributed to the development of effective methods of prevention and treatment. Moreover, research shows that LGV has probably existed for many centuries, long before it was officially documented, which is confirmed by historical sources describing similar symptoms in ancient texts.
Epidemiology
According to the World Health Organization, the prevalence of lymphogranuloma venereum varies significantly depending on the region. The highest number of cases is registered in Africa and South America, where the incidence can reach 1-4% among the population in some risk groups. In developed countries, the incidence remains relatively low, but there is an increase in cases among young people. According to statistics for 2020, about 12,000 cases were registered in Europe, which indicates the need for control and prevention of this disease. It is important to take into account that LGV is a signal of increased vulnerability to other sexually transmitted infections, which also requires careful attention to risk groups.
Genetic predisposition to this disease
To date, studies have not revealed a genetic predisposition to lymphogranuloma venereum, as the main risk factors remain behavioral aspects and the presence of other sexually transmitted infections. However, certain mutations in genes associated with the immune response may increase the body's vulnerability to infections, including chlamydial infections. Studies have shown that the interaction between chlamydia and certain polymorphisms in genes may affect the clinical manifestations and severity of the disease. However, questions of genetic predisposition to LGV require further study.
Risk factors for the development of this disease
There are several risk factors that contribute to the development of lymphogranuloma venereum, including:
- Unsecured sexual intercourse without the use of barrier contraception.
- The presence of previously suffered sexually transmitted infections.
- High frequency of change of sexual partners.
- Immune system disorders that predispose to infections.
- Social and economic factors that may limit access to health care.
All these factors may significantly contribute to the increased incidence of HIV, highlighting the importance of educational and preventive measures.
Diagnosis of this disease
The diagnosis of lymphogranuloma venereum is based on clinical manifestations and special laboratory tests. The main symptoms include:
- Enlarged lymph nodes in the groin area or other parts of the body.
- Open sores on the genitals.
- General symptoms such as fever and malaise.
Laboratory tests may include:
- Polymerase chain reaction (PCR) for the presence of Chlamydia trachomatis.
- Serological tests to detect allergens and antibodies.
Radiological examinations may be useful to more accurately assess the lymph nodes. Differential diagnosis is important to exclude other diseases, such as syphilis or lymphogranuloma caused by other infections.
Treatment
Treatment of lymphogranuloma venereum is usually performed on an outpatient basis and includes the use of antibiotics. General treatment involves:
- Pharmacological treatment, usually using antibiotics such as doxycycline or azithromycin.
- Surgical treatment, which may be necessary in case of abscesses or significant enlargement of the lymph nodes.
- Supportive care, including counselling and testing for other sexually transmitted infections.
Therefore, treatment should be started as early as possible to prevent possible complications and to reduce the risk of transmission of the disease.
List of medications used to treat this disease
The main drugs used to treat lymphogranuloma venereum include:
- Doxycycline – 100 mg, 2 times a day, for 21 days.
- Azithromycin - single dose 1 g.
- Tetracycline – 500 mg, 4 times a day, for 21 days.
It is important to take into account the individual susceptibility of the patient and the presence of concomitant diseases when choosing drugs.
Disease monitoring
Monitoring of lymphogranuloma venereum includes regular control steps such as:
- Retest for infection 3-6 months after treatment.
- Assessment of the condition of the lymph nodes to identify possible complications.
- Psychosocial support for patients and their sexual partners.
The prognosis with timely treatment is usually favorable, however, possible complications such as chronic lymphadenopathy and the development of secondary infections can significantly worsen the quality of life.
Age-related features of the disease
Lymphogranuloma venereum most often occurs in young people aged 15-30 years, but cases of the disease are also possible in older people. In older patients, the disease may manifest itself with more severe symptoms and requires special attention to concomitant diseases, which explains the need for a more detailed examination in such cases. In older people, the manifestations of the disease may be less characteristic, which complicates diagnosis and requires a more thorough approach to treatment.
Questions and Answers
- How is lymphogranuloma venereum transmitted? LGV is transmitted primarily through sexual contact, both vaginal and anal. It can also be transmitted from mother to child during childbirth.
- What symptoms indicate the need to see a doctor? The main symptoms include enlarged lymph nodes, ulcers and pain in the genital area. If these occur, you should see a doctor immediately.
- How long does the treatment for LHV last? Treatment for lymphogranuloma venereum usually takes 2 to 4 weeks, depending on the antibiotic chosen and the clinical situation.
- Can LGV be prevented? Yes, using barrier methods of contraception and regular medical examinations can significantly reduce the risk of infection.
- What is the likelihood of recurrence of the disease? With proper treatment, the likelihood of relapse is low, but under unfavorable conditions (for example, new infections) it may increase.
Advice from Dr. Oleg Korzhikov
There are a few key things to remember about lymphogranuloma venereum. First, don’t be afraid to see a doctor if you have new symptoms or suspect you may have been infected. Early diagnosis and treatment are critical to your health.
Secondly, sexual health is closely linked to overall health, so regular medical check-ups can help identify potential problems early. And finally, don’t forget the importance of open communication with your partner about your health and the risks to both of you. Prevention remains the most important part of fighting these infections, and simply using condoms can be a big step towards your health.
